[NETosis in lupus nephritis].

Tatiana Reshetnyak K S Nurbaeva I V Ptashnik A A Kudrieva Alexey A Belogurov Alexander M Lila Evgeniy Nasonov

Published in: Terapevticheskii arkhiv (2024)

Elevated levels of MPO-DNA complex were detected in 39% of patients with SLE. These patients had a higher prevalence of LN in their medical history and at the time of inclusion in the study. The correlation between MPO-DNA complex levels and the activity of LN according to SLEDAI-R indicates the potential role of MPO-DNA complex as a biomarker for assessing the activity of renal damage in SLE.

Keyphrases

circulating tumor
systemic lupus erythematosus
cell free
single molecule
end stage renal disease
ejection fraction
healthcare
chronic kidney disease
disease activity
nucleic acid
prognostic factors
risk factors
peritoneal dialysis
rheumatoid arthritis
circulating tumor cells
patient reported